The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Aratana Therapeutics Inc. | Common | 03874P101 | 21,273 | 2,118,845 | SH | SOLE | 2,118,845 | 0 | 0 | |||
| Celladon Corporation | Common | 15117E107 | 11,163 | 1,067,236 | SH | SOLE | 1,067,236 | 0 | 0 | |||
| Conatus Pharmaceuticals, Inc. | Common | 20600T108 | 7,296 | 1,192,080 | SH | SOLE | 1,192,080 | 0 | 0 | |||
| EnteroMedics, Inc. | Common | 29365M208 | 1,369 | 1,113,168 | SH | SOLE | 1,113,168 | 0 | 0 | |||
| EpiZyme, Inc. | Common | 29428V104 | 65,439 | 2,413,819 | SH | SOLE | 2,413,819 | 0 | 0 | |||
| MacroGenics, Inc. | Common | 556099109 | 66 | 3,168 | SH | SOLE | 3,168 | 0 | 0 | |||
| Mast Therapeutics, Inc. | Common | 576314108 | 1,429 | 2,551,851 | SH | SOLE | 2,551,851 | 0 | 0 | |||
| PharmAthene, Inc. | Common | 71714G102 | 11,299 | 6,347,614 | SH | SOLE | 6,347,614 | 0 | 0 | |||
| Portola Pharmaceuticals, Inc. | Common | 737010108 | 30,859 | 1,220,672 | SH | SOLE | 1,220,672 | 0 | 0 | |||
| Radius Health, Inc. | Common | 750469207 | 122,456 | 5,831,253 | SH | SOLE | 5,831,253 | 0 | 0 | |||
| Sangamo Biosciences, Inc. | Common | 800677106 | 243 | 22,487 | SH | SOLE | 22,487 | 0 | 0 | |||
| Trivascular Technologies, Inc. | Common | 89685A102 | 25,727 | 1,776,692 | SH | SOLE | 1,776,692 | 0 | 0 | |||
| Verastem, Inc. | Common | 92337C104 | 6,958 | 816,683 | SH | SOLE | 816,683 | 0 | 0 | |||